MNMD

Mind Medicine (MindMed), Inc. · NASDAQ

Sector Health Technology
Industry Pharmaceuticals: Major
Website mindmed.co
Employees(FY) 48
ISIN CA60255C8850

Performance

-9.87%

1W

-16.8%

1M

+67.07%

3M

+234.15%

6M

+124.59%

YTD

+160.95%

1Y

Profile

Mind Medicine (MindMed) Inc., a clinical stage biopharmaceutical company, develops novel products to treat brain health disorders. The company's lead product candidates include MM-120, which is in phase 2 for the treatment of generalized anxiety disorder and attention deficit hyperactivity disorder; and MM-402, a R-enantiomer of 3,4-methylenedioxymethamphetamine for the treatment of core symptoms of autism spectrum disorder. The company also develops MM-110, an a3ß4 nicotinic cholinergic receptor antagonist that has completed phase 1 for the treatment of opioid withdrawal. The company is headquartered in New York, New York.

Advanced Technical Analysis

Technical Analysis of MNMD 2024-05-10

Overview:

In analyzing the technical indicators for MNMD over the last 5 days, we will delve into the trend, momentum, volatility, and volume indicators to provide a comprehensive outlook on the possible stock price movement in the coming days. By examining these key indicators, we aim to offer valuable insights and predictions for potential inv...

See more ...

Recent News & Updates

2024-05-17 21:32
Jim Cramer's Latest Stock Picks in May 2024(Insidermonkey)
2024-05-09 23:00
Top Russell 2000 Picks: 3 Small-Cap Stocks to Scoop Up This May(Investorplace)
2024-05-09 16:01
MindMed to Participate at May Investor Conferences(Business Wire)
2024-05-09 08:00
New Studies Presented at the International Society for Health Economics and Outcomes Research Meeting (ISPOR 24) Show Growing Burden and Impact of Generalized Anxiety Disorder (GAD) in the US(Business Wire)
2024-05-09 04:01
MindMed to Participate at May Investor Conferences(Businesswire)
2024-05-08 20:00
New Studies Presented at the International Society for Health Economics and Outcomes Research Meeting (ISPOR 24) Show Growing Burden and Impact of Generalized Anxiety Disorder (GAD) in the US(Businesswire)
2024-05-08 20:00
New Studies Presented at the International Society for Health Economics and Outcomes Research Meeting (ISPOR 24) Show Growing Burden and Impact of Generalized Anxiety Disorder (GAD) in the US(Businesswire)
2024-05-08 18:49
Biotech Breakthroughs: 3 Stocks on the Verge of Revolutionizing Medicine(Investorplace)
2024-05-08 16:01
MindMed Reports First Quarter 2024 Financial Results and Business Updates(Business Wire)
2024-05-08 09:00
MNMD Stock Earnings: Mind Medicine Misses EPS for Q1 2024(Investorplace)
2024-05-08 04:01
MindMed Reports First Quarter 2024 Financial Results and Business Updates(Businesswire)
2024-05-04 08:00
MindMed Presents Phase 2b Study of MM120 for Generalized Anxiety Disorder (GAD) at American Psychiatric Association (APA) Annual Meeting in New York(Business Wire)
2024-05-03 20:00
MindMed Presents Phase 2b Study of MM120 for Generalized Anxiety Disorder (GAD) at American Psychiatric Association (APA) Annual Meeting in New York(Businesswire)
2024-05-02 07:00
MindMed to Host Conference Call and Webcast to Discuss First Quarter 2024 Financial Results and Provide Business Update(Business Wire)
2024-05-01 19:00
MindMed to Host Conference Call and Webcast to Discuss First Quarter 2024 Financial Results and Provide Business Update(Businesswire)
2024-04-25 07:00
MindMed to Present at Upcoming May Medical Conferences(Business Wire)
2024-04-24 19:00
MindMed to Present at Upcoming May Medical Conferences(Businesswire)
2024-04-07 18:59
MindMed (MNMD) Stock Rises 154% in 3 Months: Here's Why(Zacks)
2024-04-02 07:00
MindMed to Present at Upcoming April Medical Conferences(Business Wire)
2024-04-01 19:00
MindMed to Present at Upcoming April Medical Conferences(Businesswire)
2024-04-01 17:00
MindMed Announces Voluntary Delisting from Cboe Canada(Business Wire)
2024-04-01 05:00
MindMed Announces Voluntary Delisting from Cboe Canada(Businesswire)
2024-03-18 20:00
The Next Great Biotech Boom Has Arrived(Prnewswire)
2024-03-11 07:00
MindMed to Participate in the Leerink Partners 2024 Global Biopharma Conference(Business Wire)
2024-03-10 19:00
MindMed to Participate in the Leerink Partners 2024 Global Biopharma Conference(Businesswire)
2024-03-09 22:10
Weekly Roundup on the Cannabis Sector & Psychedelic Sector(Yahoo Finance)
2024-03-07 21:46
MindMed's (MNMD) Anxiety Drug Gets FDA Breakthrough Therapy Tag(Zacks)
2024-03-07 18:00
Numinus Wellness Congratulates MindMed on Positive Results from Phase 2B Clinical Trials of MM120 for Generalized Anxiety Disorder(Prnewswire)
2024-03-07 07:13
Mind Medicine (MindMed) Inc. Announces Pricing of Underwritten Offering of Common Shares and Concurrent Private Placement(Business Wire)
2024-03-07 06:00
MindMed Receives FDA Breakthrough Therapy Designation and Announces Positive 12-Week Durability Data From Phase 2B Study of MM120 for Generalized Anxiety Disorder(Business Wire)

Page 1 of 5

previousnext